Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 90 | ECE2023 | Next issue

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

Card image cap
ECE 2023 will be held in Istanbul, Turkey from 13-16 May 2023. Istanbul is known for its rich culture, historical sites and dynamic nightlife, and we are excited to come together in this city, and look forward to meeting old friends, making new ones, and sharing science, collaborations and ideas.

Rapid Communications

Rapid Communications 7: Pituitary and Neuroendocrinology 2

ea0090rc7.1 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2023

Splicing factor 3B subunit 1 (SF3B1) role in PRL-secreting PitNETs

Mangili Federica , Muro Genesio Di , Arlati Federico , Barbieri Anna Maria , E. G-Garcia Miguel , Esposito Emanuela , Treppiedi Donatella , Catalano Rosa , Marra Giusy , Nozza E mma , Locatelli Marco , Lania Andrea , Ferrante Emanuele , Sala Elisa , P. Castano Justo , M. Luque Raul , Arosio Maura , Peverelli Erika , Mantovani Giovanna

Dopamine receptor type 2 (DRD2) represents the main target for pharmacological therapy with dopamine agonists (DAs) in PRL-secreting neuroendocrine pituitary tumors (PRL-PitNET), even if about 10% of patients is resistant. A single paper recently described a somatic mutation in the gene encoding splicing factor 3B subunit 1 (SF3B1) in about 20% of patients with PRL-PitNET, that was associated with PRL hypersecretion, increased cell proliferation and invasion and reduced progre...

ea0090rc7.2 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2023

Transcription factor analysis for pituitary tumours: Are results always consistent and reliable?

Fookeerah Prishila , Varikatt Winny , McLean Mark

Background: Improved diagnostic precision is achieved with the addition of transcription factor (TF) analysis to characterise pituitary tumours. Clinicopathological studies have demonstrated a reduction in the prevalence of true null cell tumours (NC) and a rise in plurihormonal (PH) tumours, in comparison to methods based on hormone staining. There remains a high degree of heterogeneity in epidemiological and clinical patterns seen in studies. We hypothesise that variations i...

ea0090rc7.3 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2023

AZP-3813, a bicyclic, 16-amino acid peptide antagonist of the human growth hormone receptor, effectively suppresses IGF1 in beagle dogs

Ravel Guillaume , Chalmey Clementine , Berardet Corentin , Duracher David , Kurasaki Haruaki , Tomiyama Tatsuya , Reid Patrick , Culler Michael D.

Medical treatment of acromegaly is based on either suppressing pituitary growth hormone (GH) secretion or by inhibiting GH action by preventing interaction with its receptor in order to suppress the elevated levels of insulin-like growth factor 1 (IGF1). AZP-3813 is a 16-amino acid, bicyclic peptide antagonist of the GH receptor (GHR) with KD of 1.9 nM for the human GHR. Previously, AZP-3813 was demonstrated to suppress IGF1 secretion in juvenile rats in a dose-rela...

ea0090rc7.4 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2023

Effects of prolactin excess and treatment with cabergoline on bone mineral density and fracture risk in men

Del Vecchio Guendalina , Sorice Federica , Scairati Roberta , Pirchio Rosa , Meglio Sara Di , Pivonello Rosario , Colao Annamaria , Aurie mma Renata Simona

Purpose: The present study aims to investigate the effects of hyperprolactinemia (HPRL) and its pharmacological control with Cabergoline (CAB) on the risk of fractures in male patients affected by prolactinoma.Methods: Observational single-center study was conducted on 39 male patients (median age 49±12,4 y) with prolactinoma, including 37 with macroprolactinoma and 2 with empty sellae. In patients PRL levels at diagnosis (PRL 0’), PRL at evalu...

ea0090rc7.5 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2023

Evaluation and follow-up data of patients diagnosed with hypophysitis: A multicentric nationwide study

Hacioglu Aysa , Karaca Zuleyha , Uysal Serhat , Ozkaya Hande Mefkure , Kadioglu Pinar , Selcukbiricik Ozlem Soyluk , Yarman Sema , Gul Nurdan , Koksalan Damla , Selek Alev , Cetinarslan Berrin , Canturk Zeynep , Tuğce Şah unal Fatma , Corapcıoğlu Demet , Sahin Mustafa , Babayeva Afruz , Akturk Mujde , Eraydin Ayten , Fenkci Semin , Piskinpasa Hamide , Ciftci Sema , Dokmetaş Meric , Şahin Onur , Sebile Dokmetas H. , Ozturk Sadettin , Akarsu Ersin , Kılıc Kan Elif , Atmaca Aysegul , Pehlivan Esma , Saygili Fusun , Erkan Buruc , Burhan Sebnem , Omma Tulay , Uc Ziynet Alphan , Elbuken Gulsah , Bayram Fahri , Yorulmaz Goknur , Cansu Guven Baris , Bostan Hayri , Turan Kubra , Sener Selcuk Yusuf , Gorar Suheyla , Pekkolay Zafer , Hekimsoy Zeliha , Dogruel Hakan , Ertorer Melek Eda , Topaloğlu Omercan , Celik Ozlem , Iyidir Ozlem , Kelestimur Fahrettin

Background: Hypophysitis is a rare group of disease characterized with infla mmation of the pituitary gland. Rarity of the disease obviates development of a treatment strategy. We aimed to present the nationwide data of the demographics, clinical and radiological characteristics, treatment modalities and responses of the patients diagnosed with hypophysitis in a retrospective manner.Methods: The endocrinology clinics all over the country were invited to ...

ea0090rc7.6 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2023

Acquired Hypothalamic dysfunction in childhood: “What do patients need? ”

van Roessel Ichelle , de Graaf Johan , Biermasz Nienke , Charmandari Evangelia , van Santen Hanneke

Introduction: Hypothalamic dysfunction (HD) during childhood can occur due to (treatment of) a suprasellar brain tumor. HD may not only result in pituitary dysfunction, but also in severe hyperphagia, decreased energy expenditure, diabetes insipidus with adipsia, disturbance of circadian rhythm, temperature dysregulation and behavioral problems. Currently there is no effective treatment for HD while HD has major impact on quality of life. To provide optimal care and to design ...